Drug Profile
Research programme: CNS disorders - InMed Pharmaceuticals
Alternative Names: INM-900 series; Research programme: epilepsy and Huntington's disease therapeutics - InMed PharmaceuticalsLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator BayMedica; Cannabis Technologies
- Developer InMed Pharmaceuticals
- Class Antidementias; Antiepileptic drugs; Antiparkinsonians; Cannabinoids; Neuroprotectants
- Mechanism of Action Cannabinoid receptor modulators; Gene expression modulators; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease
- No development reported Epilepsy; Huntington's disease
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Huntington's-disease in Canada
- 01 Jun 2023 Pharmacodynamics data from early research studies in Neurodegenerative disease released by InMed Pharmaceuticals
- 03 Nov 2021 Preclinical developmet in Huntington's disease is still ongoing in Canada